Transient Eruptive Keratoacanthomas Associated with Nivolumab: A Case Report

Immune checkpoint inhibitors are increasingly being utilized for the treatment of advanced neoplastic disease and have been associated with cutaneous adverse effects. We are reporting a case of eruptive keratoacanthomas in a patient 24 months after initiation of nivolumab for cHL. Treatment with topical ultra-high potency corticosteroid and third generation retinoid stopped the development of new lesions and healed previous lesions. 5-FU, imiquimod, cryotherapy, and curettage are other methods to treat. Most of these were treated with topical and intralesional corticosteroids, excision, or cryotherapy. Eruptive keratoacanthoma is a rare adverse effect of immune checkpoint inhibitors. Oncologists and dermatologists must be aware of this cutaneous adverse effect as their use has been increased. Appropriate treatment can control and manage the lesions.